The z-average mean-square radius of gyration S(2)(z), the particle scattering function P(k), the second virial coefficient, and the intrinsic viscosity [eta] have been determined for amylose tris(phenylcarbamate) (ATPC) in methyl acetate (MEA) at 25 degrees C, in ethyl acetate (EA) at 33 degrees C, and in 4-methyl-2-pentanone (MIBK) at 25 degrees C by light and small-angle X-ray scattering and viscometry as functions of the weight-average molecular weight in a range from 2 x 10(4) to 3 x 10(6). The first two solvents attain the theta state, whereas the last one is a good solvent for the amylose derivative. Analysis of the S(2)(z), P(k), and [eta] data based on the wormlike chain yields h (the contour length or helix pitch per repeating unit) = 0.37 +/- 0.02 and lambda(-1) (the Kuhn segment length) = 15 +/- 2 nm in MEA, h = 0.39 +/- 0.02 and lambda(-1) = 17 +/- 2 nm in EA, and h = 0.42 +/- 0.02 nm and lambda(-1) = 24 +/- 2 nm in MIBK. These h values, comparable with the helix pitches (0.37-0.40 nm) per residue of amylose triesters in the crystalline state, are somewhat larger than the previously determined h of 0.33 +/- 0.02 nm for ATPC in 1,4-dioxane and 2-ethoxyethanol, in which intramolecular hydrogen bonds are formed between the C==O and NH groups of the neighbor repeating units. The slightly extended helices of ATPC in the ketone and ester solvents are most likely due to the replacement of those hydrogen bonds by intermolecular hydrogen bonds between the NH groups of the polymer and the carbonyl groups of the solvent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bip.21219 | DOI Listing |
Front Immunol
January 2025
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
Background: Telitacicept, a new biological agent, was approved in China for treating systemic lupus erythematosus (SLE) in 2021. Its optimal dosing for treating SLE remains unclear. Therefore, the aim of this meta-analysis is to evaluate the efficacy and safety of various telitacicept doses in SLE treatment.
View Article and Find Full Text PDFDrug Des Devel Ther
January 2025
Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, People's Republic of China.
Purpose: While esketamine shows promise as an adjunct in procedural sedation, its impact on postoperative cognitive recovery remains incompletely characterized. This study investigated the effects of esketamine on multiple dimensions of recovery, particularly cognition, in patients undergoing colonoscopy with propofol-based sedation.
Patients And Methods: We conducted this randomized, double-blinded, placebo-controlled trial from January 6, 2023, to May 20, 2024, at two hospitals in China.
Int J Cardiol Heart Vasc
February 2025
Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
Background: Epicardial fat tissue (EFT) is an active organ that can affect cardiac function and structure through endocrine, paracrine, and proinflammatory mechanisms. We hypothesized that greater thickness of EFT may harm the recovery of left ventricular (LV) systolic function in patients with severe aortic stenosis (AS) and reduced LV ejection fraction (EF ≤ 50 %) undergoing transcatheter aortic valve implantation (TAVI).
Methods: A sixty six patients with severe AS and 20 % ≥ LVEF ≤ 50 % who underwent TAVI were included.
Pak J Med Sci
January 2025
Khalid Khalil Security Forces Hospital Makkah, Makkah, Saudi Arabia.
Objective: To observe the fetomaternal outcome of therapeutic versus prophylactic blood transfusions in patients with sickle cell disease (SCD) during pregnancy.
Method: This single-center retrospective observational study was conducted on consecutive pregnant women with SCD between January 2018 and December 2020. All the pregnant women with SCD were included in this study.
J Patient Exp
January 2025
Veterans Health Administration Headache Centers of Excellence, US Department of Veterans Affairs, Orange, CT, USA.
In 2018, the Veterans Health Administration (VHA) established the original 19 Headache Centers of Excellence (HCoE) program, and an evaluation center. This study utilized a Veteran engagement group method to elicit input from Veteran patients living with chronic headache on daily needs, social determinants of health, and preferences and suggestions for headache programs, services, and research priorities. Four engagement groups were conducted between July 13 and August 22 of 2022 with Veterans who experience headache and received care at a VHA HCoE.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!